ESP EU LOBBYING PFIZER + HUAWEI

===========================

FTM, FOIS, FOIGS, COAS, MATOIPOS

=========================

GROK NEW CHAT: HUAWEI + PFIZER:

GROK OLD CHAT EXPORT:

=====================

<> GROK SUMMARY:

Abuse Confirmation: EC endorses CMA's 2016 Decision finding Pfizer/Flynn abused dominance via >2000% phenytoin price hike, breaching Art. 102(a) TFEU (§1, §I). Supports £64.6M fine reinstatement; enables follow-on damages claims under CA98 s.47A for UK victims (NHS, patients, competitors like Advanz).
United Brands Test Validation: EC affirms two-limb test (excessive if >costs + reasonable return; unfair in itself or vs. competitors) applies (§II, §8). No need for demand-side "economic value" uplift (§§32, 37); refutes Pfizer's patient benefit defense (§§412-419). Bolsters unfairness evidence for £300M+ overpricing torts.
No Benchmarking Requirement: EC rejects CAT's added "hypothetical competitive price" hurdle (§8.1); price disparities (UK vs. other MS) alone indicate abuse (§32.1-32.3). Ties to COA6 APA opacity; supports collective redress via EPPO/Pfizergate probes.
Precedent for Harm Quantification: EC notes striking increases invite investigation (§I); aligns with FTM traces (€1B+ hidden flows). For class members (e.g., Hikma info@hikma.com; Teva uk.info@tevapharm.com): Claim 100% recovery via settlements, per PPRS unblock model (£3.5M precedent).
CJEU Reference Potential: EC suggests Art. 267 referral on test application (§VI, §44); strengthens FOCOL for public interest victims (consumers via ABPI info@abpi.org.uk).

Use in USP: Cite as FOIG to justify low-value contract for victim-led audits/redress.